Immunization costs, from evidence to policy: Findings from a nationally representative costing study and policy translation effort in Tanzania

Vaughan, Kelsey; Clarke-Deelder, Emma; Tani, Kazuhide; Lyimo, Dafrossa; Mphuru, Alex; Manzi, Fatuma; Schütte, Carl; Özaltın, Annette

doi:10.1016/j.vaccine.2020.10.004

Cited by 5 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study estimated the economic cost of the measles-rubella vaccine as $4.35 per dose in US$2019 (reported as $3.99 in US$2016) [37] . Another study estimated an average economic cost of $4.71 per dose in US$2019 (reported as $4.32 in US$2016) for all routine childhood vaccines [38] . This difference is likely due at least in part to the target age group and start-up costs associated with reaching a new age group.…”

Section: Discussionmentioning

confidence: 99%

Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania

Hsiao

Struckmann

Stephani

et al. 2023

Vaccine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania

Hsiao

Struckmann

Stephani

et al. 2023

Vaccine

View full text Add to dashboard Cite

“…Some articles, focusing on vaccine supply chain per dose costs, report a range between US $0.43 and 1.21 (Mvundura et al, 2015). Others provide specific components estimations, such as cold chain (Constenla, 2015;Vaughan et al, 2020;Memirie et al, 2020), transportation (Cravioto et al, 2012), vehicles, gas price per liter and personnel costs (Vaughan et al, 2020;Portnoy et al, 2015). Some contributions interestingly distinguish between urban and rural facilities (Sch€ utte et al, 2015): delivery costs to rural centers, on average, are almost three times the costs of urban centers.…”

Section: Investments In Production Plant Andmentioning

confidence: 99%

The costs of introducing a vaccine in sub-Saharan Africa: a systematic review of the literature

Micco

Maraghini

Spadafina³

2022

IJHG

View full text Add to dashboard Cite

PurposeThis study provides a systematic literature review and categorization of the costs reported in the literature for the introduction of new vaccines, focusing on sub-Saharan Africa within LMICs, where vaccines are highly needed, financial resources are scarce and data are lacking and scattered.Design/methodology/approachA systematic literature search of PubMed and Web of Science databases was conducted according to the PRISMA requirements. Searches also included the relevant grey literature. In total, 39 studies were selected and nine cost categories were investigated to build a comprehensive framework.FindingsThe paper considers nine cost categories that cover the whole life of the vaccine, from its initial study to its full implementation, including for each of them the relevant subcategories. The systematic review, besides providing specific quantitative data and allowing to assess their variability within each category, points out that delivery, program preparation, administration and procurement costs are the most frequently estimated categories, while the cost of the good sold, costs borne by households and costs associated to AEFI are usually overlooked. Data reported on R&D costs and investment in the production plant differ significantly among the selected contributions.Originality/valueThe literature contributions on cost estimation tend to focus on a precise vaccine, a specific geographic area, or to adopt a narrow approach that captures only a subset of the costs. This article presents a rich and inclusive set of the economic quantitative data on immunization costs in limited-resource countries.

show abstract

“…Over a decade, routine immunization coverage in the United Republic of Tanzania has increased considerably, from 86% to 98% coverage of the third dose of the diphtheria-tetanus pertussis (DTP) vaccine, and from 88% to 99% coverage of the first dose of the measles-rubella vaccine (5). To maintain these Achievements and continue scaling up newer vaccines, Tanzania’s immunization program will need sufficient and effective technologies to ensure reliable, strong and efficient health supply chain system to deliver immunization services to achieve intended health outcomes (6, 7). Targeting to improve the performance of vaccines and immunization services in the country Tanzania’s Ministry of Health (MoH) through its Expanded Program for Immunization (EPI) program adopted vaccines and immunizations health supply chains management (VIHSCM) technologies and innovation such as Vaccine Information Management System (VIMS), Warehouse Management Information systems (Part of the VIMS Module) and Tanzania Immunization Registry (TImR) (8, 9).…”

Section: Introductionmentioning

confidence: 99%

Assessments of Effectiveness of Technologies Utilizations in VIHSCM Among Selected Health Facilities in Tanzania Mainland

Mollel,

Mushi,

Nkwera

2023

Preprint

View full text Add to dashboard Cite

IntroductionTanzania has adopted various technologies for Vaccine and Immunization Health Supply Chain Management to improve the availability, access, and utilization of immunization programs. However, questions remain regarding the effectiveness of the technologies in Vaccine and Immunization Health Supply Chain Management. This study assesses the effectiveness of technology on vaccine and immunization supply chain management in selected health facilities in Tanzania.MethodsThis study adopted an exploratory descriptive cross-sectional design. The study collected data using structured questionnaires from health facilities that adopted VIHSCM technologies in Arusha, Mwanza, and Mbeya regions, Tanzania. Data were analyzed using descriptive statistics and cross-tabulations with the aid of the Statistical Package of Social Sciences 23rdEdition (SPSS).ResultsThe study findings showed that 56.7% of the surveyed Health facilities had either TiMR, DHIS2, or GOTHOMIS technology used for vaccine and immunization supply chain management. The study shows that 51.4% of respondents at health facilities agreed that the adopted technologies were very effective, 45.9% were moderately effective and 2.7% said the technologies were less effective. The results asserted that 18.9 % of the adopted technologies were effective in the Management of immunization services, 37.8 % asserted that technology utilizations have Increased access to the vaccine, 2.7% said that technology utilizations assisted in monitoring vaccine temperature, 24.3% said that technologies utilizations assisted in vaccines at their respective health facilities, 5.4 % said that technologies utilizations assisted in the Maintaining the quality of Vaccines.ConclusionThis study concluded that technology plays a substantial role in improving the availability and quality of vaccines and immunization services in health facilities. Also, the study suggested that increase the use of technologies to capitalize the VIHSCM effectiveness.

show abstract

Immunization costs, from evidence to policy: Findings from a nationally representative costing study and policy translation effort in Tanzania

Abstract: Highlights: Delivery costs represent 33% of total immunization program costs in Tanzania. Costs are higher for outreach than for facility-based delivery. We used calibration methods to estimate unit and total costs. This work will inform domestic resource advocacy and planning.

Cited by 5 publications

References 23 publications

Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania

Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania

The costs of introducing a vaccine in sub-Saharan Africa: a systematic review of the literature

Assessments of Effectiveness of Technologies Utilizations in VIHSCM Among Selected Health Facilities in Tanzania Mainland

Contact Info

Product

Resources

About